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Abstract
In the past decade there have been several policy changes within the health care
community limiting access of pharmaceutical representatives to prescribers. This study
examined the impact of lack of access to pharmaceutical representatives on internal
medicine prescribers’ knowledge of medications. A web-based survey targeting
prescribers’ current practice of obtaining information about new medications, their
knowledge of two recently approved medications, and helpfulness of educational inservices by pharmaceutical representatives was conducted. Results showed the most
common methods used to gain information of medications are conferences, journals, and
word of mouth. Of the two new medications, 90% of prescribers were not at all familiar
with one and approximately half were somewhat familiar with the other. More than 70%
found the in-service education by pharmaceutical representatives very to somewhat
helpful. Overall, this study showed that limiting access to pharmaceutical representatives
has had a negative impact on prescribers’ knowledge of medications.
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Chapter 1: Introduction and Background
Pharmaceutical marketing and detailing are quintessential to the success of medications.
Historically, sales representatives had direct access to prescribers to provide product information,
samples, and product reminders, known as detailing. And while the pharmaceutical
representative’s primary goal of the interaction was promotion, a synergistic relationship was
established where the prescriber could gain invaluable information about the latest drugs and
their administration. This relationship, however beneficial, also presented the appearance of
opportunity for undue influence in the prescribing habits of clinicians. Out of public and political
concerns, the healthcare community, with support from the Office of the Inspector General of
Health and Human Services, promoted several guidances to prevent potential abuse (Rothman &
Chimonas, 2008). Consequently, the collaborative relationship between pharmaceutical
representatives and healthcare providers has dwindled. The goal of this study is to evaluate the
impact of these changes on the prescriber’s knowledge of new medications.
Pharmaceutical sales date back to the 1800s as proprietors tried to sell their snake oils
and other home-made remedies. Over time, medications became more sophisticated. The
industrial and scientific discoveries of the late 1800 and early 1900s, accompanied by several
wars, promulgated pharmaceuticals as a major commercial industry (Walsh, 2010). The 19301960s were known as the “golden age” of pharmaceuticals, as the number of medications
brought to market exploded (Daemmrich & Bowden, 2005). The industry continued to grow
during the 1980’s as several blockbuster drugs, such as Tagamet, Prozac and the first statin were
brought to market (Walsh, 2010). The pharmaceutical industry peaked in the 1990s. The cost of
prescription medications in the United States, measured by National Health Expenditures was
$2.7 billion in 1960, $40.3 billion in 1990, and $259.1 billion in 2010 (Centers for Medicare &

Medicaid Services, 2012). The peak in the annual percent increase in expenditures from the
previous year (12.8%) occurred in 1990 and has been slowly declining ever since (1.2%, 2010).
Since 2005, pharmaceutical costs have remained fairly constant at approximately 10% of total
health care expenditures (Centers for Medicare & Medicaid Services, 2012).
As medications became more abundant and sophisticated, and competition between
pharmaceutical companies skyrocketed, the need for diverse marketing techniques increased.
Consequently, the need for sophisticated sales representatives heightened. The increase in drug
sales during the 1980’s-2000 was in part due to the expanse of marketing directly to the
prescriber. From 1996 to 2000 the cost of pharmaceutical advertising tripled when it reached
$2.5 billion annually, in which eighty percent of these costs were associated with promotional
activities directed specifically towards physicians (Rosenthal, B., Donohue, Frank, & Epstein,
2002).
Prescription drug costs are currently 10% of the total health care spending in the U.S.,
totaling $263 billion (NCSL, 2013). In an effort to control spending, several states have enacted
laws which require drug companies to publicly disclose any monetary exchanges with healthcare
providers. The intention was to discourage clinicians from accepting gifts from drug companies
in return for prescribing brand name drugs and requesting these more costly drugs on
formularies. Some have argued that the process of detailing and physicians prescribing brand
named drugs instead of generics has increased the overall cost of health care in addition to costs
for the consumer (Campbell et al., 2010). Consequently, in February 2013, CMS announced its
final ruling on the “Sunshine Rule,” also known as the National Physician Payment
Transparency Program. This requires manufacturers of drugs and devices which are covered
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under any federal insurer (Medicare, Medicaid or CHIP) to report any transaction of value,
monetary or otherwise, to both physicians and teaching hospitals.
In addition to concerns of raising health care costs from pharmaceutical detailing there
was also growing concern regarding the ethics of undue influence on prescriber’s prescription
writing practices. A review of 29 empirical articles by Dr. Ashley Wazana, looked at physicians’
interactions with the pharmaceutical industry and found the relationship typically began in
medical school with drug company sponsored meals and continued to grow throughout their
careers into research funding, honoraria, and conference travel (Wazana, 2000). Several studies
have shown that receiving gifts, even small gifts, can influence people’s behaviors. One study
surveyed 467 residents and faculty at seven different academic institutions and found that a
majority of the respondents believed that any gift greater than $100 in value could potentially
influence one’s prescribing practices (McKinney et al., 1990). Studies have also shown a direct
correlation between prescriber and pharmaceutical representative interactions and increased
prescribing and formulary requests, often regardless of cost of the medication (Wazana, 2000;
Watkins, Moore, Harvey, Carthy, Robinson & Brawn, 2003; Spurling et al., 2010). As the
physician is responsible for the health and welfare of their patient, prescribing higher cost drugs
without additional benefit presents ethical concerns. Others have argued that patients are not only
directly bearing the brunt of increased costs of the prescriber-representative interaction and their
medications, but for costs of continuing education for healthcare providers as well (Schetky,
2007). At one point, almost half of all continuing education was funded by the pharmaceutical
industry (Brody, 2009).
Most healthcare providers do not feel that their behavior is influenced by detailing. In
fact, one study found that “physicians have so many ways of justifying their relationships with
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detailers that conflict-of-interest policies based on self-regulation are unlikely to succeed”
(Chimonas B. T., 2007).
Lastly, several fraud cases by pharmaceutical companies were brought to the attention of
federal and state prosecutors. From 2000 to 2004, there were 12 major cases of fraud by
pharmaceutical companies with over $4 billion in criminal and civil fines (Rothman &
Chimonas, 2008). A few specific examples are Novartis Pharmaceuticals for providing
kickbacks to physicians and pharmacies that used their products (Department of Justice, 2013);
Takeda and Abbott Labs for fraudulent billing to Medicare and kickbacks to healthcare providers
for its drug Lupron (Sillup, Trombetta, & Klimberg, 2010); and lastly, GlaxoSmithKline was
recently fined $3million for improper marketing tactics, part of which, was for kickbacks to
physicians in the form of expensive trips and entertainment (Thomas & Schmidt, 2012).
Although fraud and abuse cases are not common, they often carry great weight in the media and
have a tremendous impact on the public’s view of the pharmaceutical industry.
These issues of increasing costs, ethical concerns for practitioners, and actual fraud and
abuse cases led to several policy changes. In 1992, the American Medical Association presented
its policy, Gifts to Physicians from Industry, clearly outlining acceptable procedures for
receiving gifts with the intention to provide consistent principles of medical ethics for physicians
and other parties in the health care sector (AMA, 1998). A year later, the AMA followed this
policy with another on Continuing Medical Education (CME), which discouraged physicians
from accepting compensation for time or expenses for participating in any CME activity other
than one sponsored by their employer. The FDA presented its Guidance for Industry: IndustrySupported Scientific and Educational Activities in 1997. This guidance is intended to ensure that
programs or activities sponsored by the pharmaceutical industry are not promotional in nature by
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controlling the content and selection of material and requiring financial disclosure of involved
parties (FDA, 1997). In 2002 (and revised 2009), the Pharmaceutical Research and
Manufacturers of America (PhRMA) presented a code of actions for ethical interactions with
healthcare professionals. The PhRMA code establishes a foundation for the prescribers’ and drug
representatives’ relationship which is based on providing information that is accurate and not
misleading, does not make unsubstantiated claims, clearly balances the risks and benefits of the
product, and complies with all other FDA regulations (PhRMA, 2008). It also prevents any gifts
and limits meals provided during any presentations, either promotional or educational, to being
of modest value, not part of any entertainment or recreational event, and provided in a manner
and environment appropriate for the communication (i.e. office or hospital setting). Lastly, the
PhRMA Code prevents direct financial support for continuing education except through a third
party company or sponsor of the event who independently decides on the material presented.
Finally, The Office of the Inspector General in April 2003 presented The Compliance Program
Guidance for Pharmaceutical Manufacturers. This Guidance contains suggestions for
manufacturers to create internal controls to promote voluntary compliance with current state and
federal statutes and regulations (OIG, 2003). According to Michael Labson (2003), an attorney
who represents PhRMA and several research companies, the endorsement of the PhRMA Code
by the OIG essentially establishes “the legal requirements that govern health care marketing, and
ensures that it will be followed.”
There have been multiple impacts from these policy changes. Most notably are
restrictions placed on the pharmaceutical industry's marketing strategies. A survey of over 150
pharmaceutical executives in 2011 found that 69% felt the market was more restrictive to access
and 69% found a decrease in their sales-force access to physicians. Additionally, 50% of
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respondents plan on increasing their budget for marketing to social media sites, mobile
technologies and electronic detailing (Booz & Company, 2012). Event planners for health care
educational events are financially struggling and planning for a decrease in both sponsor and
participant attendance (Collins, 2008).
Many academic healthcare centers followed the recommendations presented in the article
Health Industry Practices that Create Conflict of Interest: A Policy Proposal for Academic
Medical Centers (Brennan et al., 2006) and formally closed their doors to pharmaceutical
representatives (Sell, 2009). According to Rothman and Chimonas (2008) over 25 public and
private medical centers and several large health care organizations, such as the Veterans
Administration, Kaiser Permanente and Henry Ford Health Systems, have all adopted a strict
limited access to drug company representatives. One study conducted in 2011 looked at the
AccessMonitor database which tracks physician and sales representative interactions
(Chressanthis, Khedkar, Jain, Poddar, & Seiders, 2012). They found access to be most
challenging in New England, the Upper Midwest, parts of the Mountain West, and the West
Coast. The data also showed an increase in restriction from 2008 to 2011 (noted by a decrease in
high access physicians from 74% to 55%). Additionally, those physicians who had greater
restriction to sales representatives were correlated with restricted flow of medical information
and consequently a reduction in their adoption of new drugs. Chressanthis et al. (2012) also
found a significant difference between primary care physicians and specialists. Specialists
embraced new medications sooner and more frequently than their primary care physicians
(PCPs) counterparts, suggesting the need for additional information and education for PCPs.
Since these recent changes in the pharmaceutical industry, especially the changes in
detailing practices, there has been very little data about the direct effect on health care
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prescribers’ practices and its direct and indirect effects on patients. Although the primary
endpoints for the changes in regulations (ethical and financial implications of prescriberrepresentative interaction) can be measured, secondary endpoints are not as easily seen,
specifically the effect of the regulations on prescribers’ knowledge of new medications and
updated information on existing products and the resultant clinical outcomes for their patients.
In light of these issues, a pilot survey was planned to better capture the current access and
knowledge of healthcare prescribers to new medications. The purpose of the study was to
determine if changes in direct access to detailing has had an impact on internal medicine
prescribers’ knowledge of new information regarding medications. Furthermore, this study
planned to assess current avenues prescribers’ use for learning about new drugs, whether
prescribers felt that they have sufficient, timely information to safely prescribe medications and
lastly if the prescriber was practicing prior to 2007, to what extent did they feel that
pharmaceutical representatives detailing aided in new medication instruction. It was predicted
that prescribers in an academic medical center, who have extremely limited access to
pharmaceutical representatives, would have limited knowledge of new medications.
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Chapter 2: Research Design and Methodology
This study involved a web-based, self-administered survey of internal medicine
prescribers at the University of Michigan Medical Center, which has a strict vendor policy and
prohibits the promotion of any drugs or devices to its staff. A descriptive research design was
used. The survey was emailed to 84 internal medicine physicians, nurse practitioners, and
physician assistants. The first page of the survey contained the informed consent which detailed
the purpose of the study, what participation involved, and risks associated with the study (see
Attachment A). To proceed to the survey, respondents had to indicate that they provided consent
to participate. The survey contained questions pertaining to access to information on new drugs
and/or significant drug updates. The survey took 5-10 minutes, and no personally identifying
information was collected.
IRB approval was obtained by Eastern Michigan University prior to distribution of the
survey (see Attachment B). Permission was also obtained by the medical directors of the Adult
Medical Observation Unit and Hospitalists program at the University of Michigan (see
Attachments C). Participants were notified that involvement was completely voluntary and they
would have to actively connect to a link to access the survey after reading and agreeing to the
informed consent. Data collected were anonymous and encrypted. Following the completion of
the study and all analyses, all data will be destroyed.
The survey consisted of fourteen questions (see Attachment A). The first four questions
were demographic in nature. These questions gained information about degree status, years in
practice, prescribers’ age, and patient population they care for. One question was designed to
obtain information about how prescribers access new drug information (conferences, journals,
peers/word of mouth, Internet/web sites, phone applications, email alerts or other). Four
8

questions were devoted to testing prescribers’ knowledge of two medications and the prescribers’
comfort level of prescribing with their current knowledge of the medication. The medications
were chosen from the FDA website for medications approved from January-March 2013
(approximately one year prior to the study start). The medications were selected based upon a
disease process that would be universally managed by an internal medicine physician. Based on
these criteria, Invokana™ (canagliflozin) and Suprax® (cefixime) were selected. Invokana™ is
an oral medication for the treatment of Type II diabetes that was approved by the FDA on March
29, 2013. Suprax® is a cephalosporin antibiotic approved for both adults and pediatric use on
March 26, 2013. From 1980-2003 Suprax® was used for treating Neisseria gonorrhoeae (Center
for Disease Control, 2008). It was removed from the market by Wyeth Pharmaceuticals once its
patent expired due to its small volume of sales. Lupin Pharmaceuticals purchased the license and
began marketing the drug as a branded generic (Golani, 2011). This drug was chosen to compare
prescribers’ knowledge and comfort level of the drug prior to 2003 (with detailing) and those
practicing after (without detailing) to determine if there were any differences. The last four
questions were devoted to those prescribers that were in practice prior to the institution of the
PhRMA code. The first question was a yes/no. If the participant answers “no” the survey ended.
If the participant answers “yes” an additional three questions were included with a Likert scale
response. Options were provided ranging from 1-5. The first question concerned how helpful the
prescriber found the in-service education by the pharmaceutical representative. This was
followed by two additional questions of how the in-service education impacted their patient care
decisions and if they found the in-service education helpful for their current practice. The last
question was open ended for comments. Univariate and bivariate analyses were conducted to
analyze the data.
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Chapter 3: Results
The survey was sent to 84 internal medicine prescribers from the Medical Faculty
Hospitalist group and the Adult Medical Observation Units at the University of Michigan. The
participants of the study included 41 subjects (see Table 1), which was a 48.8 % response rate.
The majority (92.7%, n = 38) were physicians while 7.3% (n = 3) were physicians assistants.
The majority of the participants were under the age of 40 (68.3%, n = 28) and almost all were
under the age of 50 (87.8%, n = 36). More than half of the sample had been practicing for 10
years or less (65.8%, n = 27). Most participants worked with an adult population (82.9%, n =
34) or both adults and children (14.6%, n = 6); only one participant worked solely with children
(2.4%).
Frequencies were calculated to describe the avenues participants used to learn about new
information about medications (see Table 2). The three most popular methods involved
“traditional” information channels including conferences (82.9%, n = 34), journals (80.5%, n =
33), and word of mouth (85.4%, n = 35). Newer electronic avenues were also used but less
frequently; these included email (36.6%, n = 15), Internet (70.7%, n = 29), and mobile apps
(22.0%, n = 9). T-tests were conducted to determine whether participants who used each of the
different modalities of information differed from those who did not use them in terms of age and
years of practice; no significant differences between the groups were obtained. Furthermore,
chi-square tests were conducted to determine whether participants who used the avenues differed
from those who did not in terms of the degree of the participant (MD or NP vs. physician’s
assistant) and patient population in which they practice (adult, pediatric, or both). Physician
assistants were less likely than physicians to obtain information by word of mouth (33.3% vs
86.6%, χ2 = 6.2, p<.05). However, there were only 3 physician assistants included in these
10

analyses, and thus the findings should be taken with caution. No differences were found based on
patient population.
Table 1
Demographic Characteristics of Participants Included in the Analyses
Number

Percentage

MD

38

92.7

NP

0

0

PA

3

7.3

28-40 years

28

68.3

41-50 years

8

19.5

50 years +

5

12.2

< 10 years

27

65.8

> 10 years

14

34.2

Adults

34

82.9

Pediatrics

1

2.4

Both

6

14.6

Degree

Age

Years of Practice

Patient Population

Note: Total number of respondents is 41.
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Table 2
Frequency of Use of Modalities to Learn About New Medications
Modality
Number
Percentage
Conferences

34

82.9

Journals

33

80.5

Word of Mouth

35

85.4

Email

15

36.6

Internet

29

70.7

Mobile Applications

9

22.0

Note: Percentages do not equal 100% as respondents could select all that apply.

Table 3 presents the results regarding participants’ familiarity and comfort prescribing
two recently approved prescription drugs, specifically Suprax® and Invokana™. Overall,
participants were unfamiliar with the two medications. Nine out of 10 participants (90.2%, n =
37) reported that they were “not at all familiar” with Invokana™ and a similarly high number
(87.8%, n = 36) reported being “not at all comfortable” prescribing the medication. Familiarity
and comfort with Suprax® was higher than with Invokana™. Approximately half of participants
(51.2%, n = 21) reported being at best “somewhat familiar” with the medication and a similar
number (48.8%, n = 20) reported being at best “somewhat comfortable” with prescribing the
medication. T-tests were performed to determine if participants’ background in terms of age,
years in practice, degree, and patient population were related to the familiarity and comfort in
prescribing these medications, and no significant differences were shown.
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Table 3
Number and Percentage of Respondents who were Familiar and Comfortable with
Prescribing Invokana™ and Suprax®.
Invokana™

Suprax®

Number

Percentage

Number

Percentage

Not at all

37

90.2

8

19.5

A little

3

7.3

8

19.5

Somewhat

1

2.4

14

34.1

Moderately

0

0

6

14.6

Very much

0

0

5

12.2

Not at all

36

87.8

6

14.6

A little

3

7.3

5

12.2

Somewhat

2

4.9

9

22.0

Moderately

0

0

13

31.7

Very much

0

0

8

19.5

Familiar with

Comfortable with

Analyses were also conducted to determine the participants’ perceptions of whether inservice educational resources were needed and perceptions of drug representatives (if the
participant had been practicing prior to 2007). When asked about whether pharmaceutical inservice education would be helpful, the 21 participants who had been practicing prior to 2007
were more likely than the 19 who had not to report that in services would be valuable (practicing
prior = 2.57, not practicing prior = 1.89, t = 1.85, p<.10); these results showed a trend towards
significance, suggesting further research is warranted prior to drawing conclusions.
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Examination of the ten open ended responses about drug representatives indicated that
those who had been practicing prior to 2007 had a more nuanced perception, with 50% of those
respondents reporting positive benefits. While both groups tended to note the possibility of drug
representatives providing biased information, those who had actual experience with drug
representatives noted some ways in which they were valuable. For example, the following were
stated by physicians who had been practicing prior to 2007:
“In the past I found Drug Reps to be honest. They gained favor by just
being more present. The bias for me was that the generic medications did
not get represented.”
“Pharmaceutical reps come with bias of selling but do provide insight
about the drug mechanisms of action, data on efficacy, precautions needed
which are helpful. This is now missing, esp. when you read an app – you
are sure re: most common side effects – as all get listed in no particular
order”
In contrast, of the ten open ended responses the two participants who had not been
practicing prior to 2007, and had no direct experience with pharmaceutical representatives, were
more likely to have singularly negative views. For example,
“Drug reps might have useful theoretical info, but I don’t believe that
they have much knowledge applicable to real life patient care. And if
they’re pushing a med, it’s probably new and expensive and my patients
can’t afford it.”
Examination of the follow-up questions about the experiences of those who had been
practicing prior to 2007 provided additional information about how the presence of the drug
representative was perceived by prescribers (see Table 4). Among this group, 38.1% (n = 8)
found in services by drug representatives to be moderately or very helpful, 33.3% (n = 7) found
the services to be somewhat helpful, and 28.6% (n = 6) found the services to be “not at all” or “a
little” helpful. In terms of influencing care, 66.7% (n = 14) reported that drug representatives
had “no influence” or “a little.”
14

Table 4
Number and Percentage of Participants Practicing Prior to 2007 who Report Value of In-service
Education and Influence on Patient Care.
Number Percentage
Value of Service
Not at all

3

14.3

A little

3

14.3

Somewhat

7

33.3

Moderately

6

28.6

Very much

2

9.5

Not at all

5

23.8

A little

9

42.9

Somewhat

6

28.6

Moderately

0

0

Very much

1

4.8

Influence on Patient Care

Note: The total number of participants who had been practicing prior to 2007 is 21.
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Chapter 4: Discussion
The purpose of the study was to evaluate the impact of the lack of direct detailing on
prescribers’ knowledge of new medications. An online survey was conducted with internal
medicine prescribers at a large academic medical center who has strict vendor policies. Findings
from this study support the notion that prescribers do not feel they have adequate information
regarding new medications to confidently prescribe. Methods for obtaining information on new
medications varied among the respondents and had no correlation between the prescriber’s age
and years of practice. Moreover, there were mixed opinions about the value of the
pharmaceutical representatives’ direct in-service education.
Results from this study indicate that prescribers are using multiple avenues to learn about
new drugs in 2014, seven years following the policy change. Information about new drugs was
most commonly obtained from conferences, journals and word of mouth. Technological sources
(email, Internet and mobile apps) were used less frequently; however, these sources appear to be
gaining in popularity. The commonly used sources (conferences, journals, and word of mouth)
raise concerns about the quality and breadth of the knowledge gained. All of these methods
require prescribers to be active participants in seeking information about new medications. Their
scope is limited by personal selectivity, financial, and potentially geographical and political
access. Even more concerning is one of the most common ways physicians gather information,
word of mouth. Word of mouth can be inaccurate, bias, incomplete, and could potentially cause
more harm. Regardless of the manner in which healthcare providers gain their information, it is
imperative that the information be timely, accurate, and complete. It behooves the medical
community to ensure that the sources of this data are able to meet these standards. It is with this
intent that the changes in the PhRMA code were made, but unfortunately the changes appear to
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have created an atmosphere of distrust rather than cooperation and sharing of invaluable
information.
Additional support for the impact of these policy changes can be seen by the responses of
the prescribers and their current knowledge and comfort with prescribing two different
medications. Nine out of 10 prescribers were not at all familiar with a new diabetic medication
(Invokana™), and half of the respondents were at best “somewhat familiar” with the new
cephalosporin Suprax®. Their lack of knowledge was similarly reflected in their lack of comfort
in prescribing and caring for a patient on these medications. There was no correlation noted
between those physicians who were practicing prior to the removal of Suprax® in 2003 and the
knowledge or comfort of the drug. This suggests that the limited knowledge the clinicians did
have comes from a generalized knowledge of the drug class. The results from this study about
these two drugs provide specific examples as to the lack of information available for health care
prescribers and the implications for their confidence to prescribe these medications. This also
brings to light the need for pro-active education of healthcare providers. This study found that
the majority of the healthcare providers were not familiar with these new medications, which
were approved by the FDA a year prior. Learning about a new medication by a patient admitted
under your care in the hospital is not the time or place to fully appreciate the associated drug
interactions and precautions.
Lastly, a trend was found amongst those prescribers who were practicing prior to 2007
and had experience with pharmaceutical detailing in favor of the in-service education. Although,
most respondents stated they were aware of bias in the material provided by the pharmaceutical
representative, two-thirds found the information to be somewhat to very helpful. For example,
one participant emphasized that precautions were necessary, but the encounters did provide
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information about the drug mechanisms, actions, and efficacy. Overall, these findings suggest
that there are inadequate resources for prescribers to obtain information about new drugs.
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Chapter 5: Conclusions and Recommendations for Further Research and Action
The ability of healthcare providers to stay up to date with new technology, medications,
health trends, and information is imperative. The policy changes in the past decade limiting
direct access to pharmaceutical representatives have made access to this information even more
difficult for prescribers. Although there may be more avenues to gain information today than
several decades ago, there is an increased burden upon the provider to actively pursue and obtain
the information, with potentially less oversight of the content and validity of the source. In many
ways the PhRMA code was designed to protect the integrity of the information; however, many
institutions have taken the guidance to an extreme and completely denied access of
pharmaceutical companies to their healthcare providers without a contingency plan to fill the
void of information that was left. Although pharmaceutical companies are still allowed to present
continuing education material through a third party vendor, the burden falls on the clinicians to
seek out and arrange the interaction, which again places the burden upon the healthcare provider.
This void in educational information needs to be addressed without placing further burden upon
the provider to seek out quality information.
This study was limited by its small sample size; therefore, additional studies with larger
sample sizes should be conducted. Specifically, larger samples from each prescriber group (MD,
PA, and NP) as well as by clinical specialty should be examined for modes and access to new
medication information, as tailoring education to different healthcare providers may be
necessary. A comparative study of several different types of healthcare facilities (academic,
private, inpatient, or outpatient) with varying ranges in access to detailing should be explored to
better identify healthcare providers knowledge of new medications and amount and type of
interaction with drug representatives.
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Lastly, further exploration needs to address the growing technological applications for
medical information to assess for validity, and ease of use, as well as detailed marketing reports
of the end users. This may have more of an impact on consumers, as most healthcare prescribers
have access to regulated Internet sites through the institution in which they work.
Overall, this study has identified an increased need to provide pro-active education to
healthcare prescribers about new medications in a timely, accurate, and unbiased manner. Direct
detailing of the pharmaceutical representative to health care prescribers has indeed been reduced
by changes in the PhRMA Code and additional resulting polices. It appears the negative aspects
of detailing overshadowed the positive, and the medical field has now swung the pendulum in
the other direction and has become too restrictive. Detailing provided an invaluable exchange of
information, which has now been lost to several institutions, especially academic medical centers
that have a stricter “no vendor policy.” This void was intended to be filled by an unbiased third
party to provide education, although this study clearly shows the present system is not meeting
the current needs of healthcare prescribers. Perhaps, future studies need to address the ease of
access, timeliness, and relevance of content by third party continuing education providers,
especially at academic medical centers.
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Attachment A: Survey Questions

Prescribers’ Knowledge of New Medications
INFORMED CONSENT
Project Title: Internal Medicine Prescribers’ Knowledge of Medications and Effect of 2007
PhRMA Code
Investigator: Patricia J. Brink, Eastern Michigan University
Co-Investigator: Irvin G. Martin, PhD Chair
Purpose of the Study: I am a graduate student at Eastern Michigan University. This survey is
part of a master’s thesis and involves research. The purpose of this research study is to gain a
better understanding of the relationships between health care providers who can write
prescriptions (prescribers’), their knowledge of new medications and access to pharmaceutical
sales representatives.
Procedure: This email has been sent to you for participation in a research study. The purpose of
the study is to gain information about how prescribers acquire knowledge about new
medications. Information is included on who to contact should you have additional questions. If
you are in agreement with participation in this study, your consent will be noted by checking the
appropriate box below. The survey contains 14 questions. One is open ended for your comments;
all other questions are check boxes. You will be asked to complete questions about your
demographic information, including your degree, age, and years of practice. Additional questions
will be asked about where you obtain information about new medications and your opinions
about in-services provided by pharmaceutical representatives.
The email will be sent out twice, two weeks apart. The survey only needs to be submitted once.
Other than the two emails, this is a one-time interaction for completion and submission of the
questionnaire. No follow up interactions will be performed. The approximate total time to
complete the questionnaires should be about 5-10 minutes.
Confidentiality: All information collected is anonymous. At no time will your name be
associated with your responses. Information will be encrypted prior to the investigators review.
All related materials will be kept in locked file cabinets in the researcher’s office and electronic
data will be stored on a password-protected computer. All data will be destroyed once the study
is complete.
Expected Risks: There are no foreseeable risks to you by completing this survey, as all results
are anonymous and will be kept completely confidential.
Expected Benefits: There will be no direct personal benefit to you, but your participation will
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contribute to our understanding of how prescribers’ get information about new medications.
Voluntary Participation: Participation in this study is voluntary. You may choose not to
participate. If you do decide to participate, you can change your mind at any time and withdraw
from the study without negative consequences.
Use of Research Results: Results will be presented in aggregate form only. No names or
individually identifying information will be revealed. Results may be presented at research
meetings and conferences, in scientific publications, and as part of a master’s thesis being
conducted by the principal investigator.
Future Questions: If you have any questions concerning your participation in this study now or in
the future, you can contact the Principle Investigator, Patricia Brink at pbrink1@emich.edu, or
734-255-3987.
This research protocol and informed consent document has been reviewed and approved by the
Eastern Michigan University Human Subject Review Committee for use from March 1, 2014 to
April 30, 2014. If you have any questions about the approval process, please contact CHHSHSRC, Chair Dr. Jayne Yatczak, jyatczak@emich.edu, 734-487-0461.
Print this screen for future reference.

1.

Consent to Participate: I have read or had read to me all of the above information about
this research study, including the research procedures, possible risks, side effects, and the
likelihood of any benefit to me. The content and meaning of this information has been
explained and I understand. All my questions, at this time, have been answered. I hereby
consent and do voluntarily offer to follow the study requirements and take part in the
study.
No, I choose not to participate in this research study
Yes, I choose to participate in this research study

2.

What is your degree?
MD or DO
PA
NP

3.

How many years have you been practicing?
0-5
5-10
10-15
15-20
28

20-25
25+
4.

What is your age?
28-35
36-40
41-45
46-50
51-55
56-60
60+

5.

What patient population do you work with?
Adults
Pediatrics
Both

6.

How do you get information on new medications? Check all that apply.
Conferences
Journals
Peers or word of mouth
Internet or web sites
Mobile phone applications
Email alerts
Other
Please specify:

7.

Are you familiar with Invokana™ canagliflozin?
Not at all
29

A little
Somewhat
Moderately
Very much
8.

Based on your current knowledge of Invokana™ canagliflozin, how comfortable would
you be prescribing or caring for a patient on this medication?
Not at all
A little
Somewhat
Moderately
Very much

9.

Are you familiar with Suprax® cefixime?
Not at all
A little
Somewhat
Moderately
Very much

10.

Based on your current knowledge of Suprax® cefixime, how comfortable would you be
prescribing or caring for a patient on this medication?
Not at all
A little
Somewhat
Moderately
Very much

11.

Were you practicing when pharmaceutical representatives provided in-services on new
medications?
Yes
No

12.

How helpful did you find the in-services for providing information about new
medications?
Not at all
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A little
Somewhat
Moderately
Very much
13.

How much did the in-services impact your patient care decisions?
Not at all
A little
Somewhat
Moderately
Very much

14.

Would you find in-services by drug representatives helpful in your current practice?
Not at all
A little
Somewhat
Moderately
Very much

15.

Comments:
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